Asthma And COPD Market Analysis | Coherent Market Insights

1. Coherent Market InsightS Market Research and Business Consulting Services https://www.coherentmarketinsights.com/ COVID-19 Impact Tracker

2. Asthma & COPD Market Analysis (2020-2027) • Chronic Obstructive Pulmonary Disease (COPD) is characterized by a persistent blockage of airflow in the lungs, which results in abnormal sputum, more than a “smoker’s cough” or a chronic cough and breathlessness. Symptoms of COPD include, cough, breathlessness (shortness of breath) and wheezing, sputum, chest infections, weight loss, tiredness, and ankle swelling. • The global asthma and COPD market is estimated to account for US$ 30,710.2 Mn in terms of value in 2020 and is expected to reach US$ 42,608 Mn by the end of 2027.

3. Global Asthma and COPD Market: Drivers • Increasing prevalence of COPD is expected to propel growth of the global asthma and COPD market over the forecast period. For instance, according to a report by Global Initiative for Chronic Obstruction Disease’s 2018 report, COPD is expected to result in 4.5 million global deaths annually by 2030. • Moreover, increasing member of smokers is also expected to aid in growth of the market. For instance, according to the World Health Organization, 1.337 billion people smoked tobacco worldwide in 2018. • Combination Therapies held dominant position in the global asthma and COPD market in 2019, accounting for 57.0% share in terms of value, followed by Bronchodilators and Anti-Inflammatories, respectively.

4. Figure 1. Global Asthma and COPD Market Share (%), by Value, by Drug Type, 2019

5. Global Asthma and COPD Market: Restraints • High cost of asthma treatment is expected to hinder growth of the market. For instance, the annual per-person medical cost of asthma is around US$ 4,000 in the U.S. • Moreover, asthma treatment is a long process and patients affected with the disease have to follow many precautions. Very often patients discontinue the treatment halfway because of high cost. This is also expected to limit the market growth.

6. s

7. Figure 2. Global Asthma and COPD Market Value (US$ Mn), and Y-o-Y Growth (%), 2019-2027

8. Market Trends/Key Takeaways • Major organizations are focused on offering guidelines regarding management of asthma during the Covid-19 pandemic. For instance, in July 2020, Asthma and Allergy Foundation of America released a comprehensive guide, the “COVID-19 and Asthma Toolkit for Schools” to help educators and families of children living with asthma navigate best methods to stay healthy for those returning to classrooms during the COVID-19 pandemic. • R&D of novel therapies is expected to propel growth of the global asthma and COPD market. For instance, the study, ‘Masitinib Significantly Decreases the Rate of Asthma Exacerbations in Patients with Severe Asthma Uncontrolled by Oral Corticosteroids: A Phase 3 Multicenter Study’, reported in June 2020, stated that Masitinib significantly reduced asthma exacerbations in patients with severe asthma uncontrolled by oral corticosteroids compared with placebo treatment.

9. Global Asthma and COPD Market: Competitive Landscape • Major players operating in the global asthma and COPD market include, AstraZeneca, Novartis AG, GlaxoSmithKline plc, Merck & Co., Verona Pharmaplc,, Regeneron Pharmaceuticals, Inc., GlaxoSmithKline plc, and BoehringerIngelheim GmbH.

10. Global Asthma and COPD Market: Key Developments • Major players in the market are focused on R&D of new therapies to expand their product portfolio. For instance, in July 2020, AstraZeneca's results from the positive Phase III ETHOS trial were published in the New England Journal of Medicine. The study demonstrated that the triple-combination therapy PT010 (budesonide/glycopyrronium/formoterolfumarate) reduced the rate of moderate or severe exacerbations compared with two dual-combination therapies in patients with moderate to very severe COPD. • Major players in the market are also focused on approval and launch of new products to expand their product portfolio. For instance, in February 2020, European Medicines Agency accepted GlaxoSmithKline plc’s regulatory submission seeking an additional indication for the use of once-daily, single-inhaler triple therapy, TrelegyEllipta (fluticasone furoate/umeclidinium/vilanterol or FF/UMEC/VI) for the treatment of asthma in adults.

11. Request sample copy here • Request PDF brochure here • Request Customization here • Talk to Analyst • Buy Now • Reference: • https://www.coherentmarketinsights.com/market-insight/asthma-and-copd-market-4002

12. About Us: • Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. • What we provide: • Customized Market Research Services • Industry Analysis Services • Business Consulting Services • Market Intelligence Services • Long term Engagement Model • Country Specific Analysis

13. Contact Us: • Mr. Shah • Coherent Market Insights Pvt. Ltd. • Address: 1001 4th ave, #3200 Seattle, WA 98154, U.S. • Phone: +1-206-701-6702 • Email :sales@coherentmarketinsights.com

14. Thank You! Kindly follow CMI Social Media Profiles for the latest company updates Facebook Linkedin Twitter https://www.coherentmarketinsights.com/